Skip to main content

Day: December 3, 2019

Aura Systems Inc. Fulfills Initial 115 Unit Order on Schedule

STANTON, CALIFORNIA, Dec. 03, 2019 (GLOBE NEWSWIRE) — Aura Systems, Inc. (OTCBB: AUSI) announced today that it has fulfilled the balance of CBOL Corporation’s initial order of 115 AuraGen® units on schedule during the company’s third quarter ending November 30, 2019.CBOL Corporation placed an initial order of approximately 115 AuraGen® units in August 2019 with all units scheduled to be delivered by the end of November 2019. “That we have timely shipped more than 115 AuraGen® units since July 2019 is an important step in that we have demonstrated that Aura is now reliably delivering quantities of product on schedule” explained Aura’s President, Ms. Cipora Lavut. “From July 2019 to-date, Aura has already delivered more product than during the past four years combined” explained Dr. Robert Lempert,...

Continue reading

Canbiola Launches First Capsule Hemp Extract Product

New Delivery Format Expected to Open Additional OpportunitiesHICKSVILLE, NY, Dec. 03, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of hemp-derived THC-Free Cannabidiol (CBD) Isolate products such as oils, drops/tinctures, creams, moisturizers, chews, and capsules, announced today that it has launched Canbiola Turmeric & Ginger Pure Hemp Extract in 30MG capsules. The 30-count capsules bottle retails for $59.99 and is available at https://canbiola.com/softgels-capsules-1/.Canbiola Chief Executive Officer Marco Alfonsi commented, “The market and our partners and customers have been asking for new delivery formats, specifically capsules. We are pleased to be able to meet their demands and look forward to additional...

Continue reading

COMPAGNIE LEBON : Paluel-Marmont Capital, filiale prend une participation majoritaire dans Quadrilatère, spécialiste du Space Planning

COMMUNIQUÉ DE PRESSE                                                                                                                                                               Paris, le 3 décembre 2019PALUEL-MARMONT CAPITAL prend une participation majoritairedans QUADRILATERE, spécialiste du Space PlanningQuadrilatère est un pure player de l’aménagement d’espaces tertiaires, principalement de bureaux, essentiellement en région parisienne.Au service des propriétaires-bailleurs ou des directions générales des entreprises occupantes, spécialiste des surfaces de 500 à 50 000 m², Quadrilatère travaille aussi bien pour de grandes entreprises et des ETI, que pour des sociétés d’investissements, des cabinets d’avocats, des sociétés de conseil… Ses équipes oeuvrent à la conception et à la réalisation d’espaces de travail intelligents...

Continue reading

Arcus Update on Sale of Dan Man Property

VANCOUVER, British Columbia, Dec. 03, 2019 (GLOBE NEWSWIRE) — Arcus Development Group Inc. (TSX-V:ADG)(“Arcus”) announces that further to its news release of October 23, 2019, the British Columbia Securities Commission has issued an exemption order (the “Exemption Order”) permitting Arcus to proceed with the sale of its Dan Man property to Goldcorp Kaminak Ltd. (“Goldcorp Kaminak”) a subsidiary of Newmont Goldcorp Corporation.In partial consideration of the sale of the Dan Man property pursuant to the term of a property purchase agreement dated October 22, 2019, Goldcorp Kaminak will return 14,400,000 Arcus shares (the “Shares”) to Arcus.  The Shares were originally sold to Goldcorp Inc. in October of 2016 as part of a structured financing.  The Exemption Order has been made under Section 114(2) of the British Columbia Securities...

Continue reading

Europäischen Arzneimittelagentur akzeptiert Prüfung des Antrags auf Genehmigung für das Inverkehrbringen von Amarins Icosapent-Ethyl (Vascepa®) zur Reduzierung des kardiovaskulären Risikos für Hochrisikopatienten gemäß der REDUCE-IT®-Studie

DUBLIN, Irland und BRIDGEWATER, New Jersey, Dec. 03, 2019 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ: AMRN), ein Pharmaunternehmen, das seinen Schwerpunkt auf der Verbesserung der kardiovaskulären Gesundheit hat, gab heute bekannt, dass die Europäische Arzneimittel-Agentur (EMA) den Antrag auf Genehmigung für das Inverkehrbringen (MAA) von Icosapent-Ethyl (Markenname Vascepa® in den USA) als Behandlungsform zur Reduzierung des Risikos kardiovaskulärer Ereignisse bei Hochrisikopatienten, deren Cholesterinspiegel mittels Statintherapie kontrolliert werden, die jedoch erhöhte Triglyceridwerte von 135 mg/dl oder mehr sowie andere kardiovaskuläre Risikofaktoren aufweisen, validiert. Mit der Validierung wird bestätigt, dass die Einreichung des Antrags für Vascepa ausreichend vollständig ist, so dass die EMA mit dem Prüfungsverfahren...

Continue reading

Neptune Dash Technologies Announces No Material Change

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Dec. 03, 2019 (GLOBE NEWSWIRE) — Neptune Dash Technologies Corp. (TSX-V: DASH) (“Neptune” or the “Company”) is issuing this press release in response to a request by the Investment Industry Regulatory Organization of Canada to comment on recent trading activity of its common shares. The Company announces that it is not aware of any material undisclosed developments and has no material information or change to report at this time. Neptune is also unaware of any material undisclosed change related to the Company that would explain the recent movements in the price of its common shares. The Company will keep the market informed as required.About Neptune Dash Technologies Corp.Neptune primarily builds and operates...

Continue reading

Communiqué sur la modification de caractéristiques des ORA et des BSA

Foncière Paris NordSociété Anonyme au capital de 826 289,77 euros Siège social : 15, rue de la Banque – 75002 Paris RCS Paris 542 030 200Paris, le 3 décembre 2019Communiqué sur la modification de caractéristiques des ORA et des BSAL’Assemblée Générale des obligataires du 3 décembre 2019 a approuvé la prorogation de quatre ans de la durée d’exercice des Obligations Remboursables en Actions (ORA), dont l’échéance est désormais fixée au 04 décembre 2023. La parité de remboursement demeure inchangée : une ORA donne droit à une action nouvelle.L’Assemblée Générale des titulaires des Bons de Souscription d’Actions (BSA) du 3 décembre 2019 a approuvé la modification du prix d’exercice des BSA, qui s’élève désormais à 0,05€ par BSA, la parité demeure inchangée : un BSA donne droit à deux actions nouvelles. Elle a, également, approuvé la...

Continue reading

Les Hôtels Baverez : Nombres d’actions et de droits de vote au 30 novembre 2019

LES HOTELS BAVEREZ S.A.2, place des Pyramides 75001 PARISCapital € 10.127.050 – Code NAF 5510 ZR.C.S. PARIS 572 158 558ISIN : FR 0007080254Mnémonique : ALLHBEURONEXT GrowthNombres d’actions et de droits de vote au 30/11/2019Au 30 novembre 2019, le nombre total d’actions composant le capital social de la société s’élève à 2 372 468.Le nombre total de droits de vote à la même date est de 3 854 371.Pièce jointeDeclaration_AMF-DDV_au_30_11_19

Continue reading

Japan: Orege announces the sale of its first two SLGF® solutions to the Itochu group

Japan: Orege announces the sale of its first two SLGF® solutions to the Itochu groupVoisins-Le Bretonneux, 3 December 2019, 8amUnder the partnership set up one year ago with Itochu Machine-Technos Corp. (ITCMT), a subsidiary of the Japanese group Itochu Corporation, to distribute and integrate Orege’s solutions, Orege is delighted to announce its first firm sale of two SLG® + Flosep® solutions to ITCMT.The first SLG® + Flosep® solution will be installed and implemented, by joint teams from Itochu and Orege, for a Japanese group that is amongst the world leaders in the paper and packaging industry.The SLG® solution will be used to condition biological sludge upstream from a belt filter press.The SLG® solution deployed aims to significantly improve performance for the sludge treatment line, which is currently overloaded:Reducing the volume...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.